Professional Documents
Culture Documents
Duravest Management Change Press Release
Duravest Management Change Press Release
CHICAGO, IL -- (MARKET WIRE) -- September 13, 2006 -- Duravest, Inc. (PINKSHEETS: DUVT) (XETRA: DUV), the global
leader in investing in and developing convergent medical technology firms, has announced that the Board of Directors
appointed effective immediately the renowned biophysics researcher Prof. Dr. Hans-Albert Kolb as chairman of the board
and Hendrik Hammje, experienced investment banker, as its interim CEO. Prof. Dr. Kolb will lead Duravest's investment
strategy development and will contribute through his extensive network to the identification of new technologies and potential
investments. Mr. Hammje, in his role as Duravest interim CEO, will be in charge of the company's day-to-day operations and
will seek to maximize shareholder value through the evaluation and execution of new transactions.
Duravest has also accepted with great regret the resignation of Dr. Ogan Gurel as Duravest Director and CEO, who is
resigning for personal reasons and to pursue other activities. The Board of Directors wishes him well in his future ventures.
Dr. Gurel contributed tremendously to both conceiving of and developing the Duravest model. Dr. Gurel has also attracted
world-renowned scientists and physicians and top opinion leaders who together have been invaluable to the growth of the
company. These highly esteemed experts are highly regarded in their own respective fields of clinical and scientific research
and Duravest will continue to benefit from them in their advisory roles.
Borys Chabursky, member of the Duravest Board of Directors, commented, "We are sorry that Dr. Gurel has resigned his
position as CEO of Duravest. His contributions to the company over the past year -- given his unique clinical, scientific and
business expertise -- helped to make Duravest one of the leaders in convergent medical technologies."
Rolf Huber, Duravest Board member, added, "At the same time, we also are delighted at the prospects of Duravest's future
with the leadership of Prof. Dr. Kolb and Mr. Hammje, both of whom have made significant contributions to their respective
professions. We believe this combination will take Duravest into its next phase of growth and development consolidating on
the vision that Dr. Gurel has initiated."
Press Contact:
Michael Tew & Alexandra Preate
CapitalHQ
(212) 588-9148
mtew@capitalhq.com or apreate@capitalhq.com